Compounds > metformin
Page last updated: 2024-10-30

metformin and Esophageal Neoplasms

metformin has been researched along with Esophageal Neoplasms in 46 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Esophageal Neoplasms: Tumors or cancer of the ESOPHAGUS.

Research Excerpts

ExcerptRelevanceReference
" A large prospective study is expected to elucidate the specific risk of the 90% subtype of esophageal cancer, esophageal squamous cell carcinoma (ESCC), with metformin therapy."7.96Association Between Metformin Use and Risk of Esophageal Squamous Cell Carcinoma in a Population-Based Cohort Study. ( Lagergren, J; Ness-Jensen, E; Santoni, G; Wang, QL; Xie, SH, 2020)
"The dysregulation of Fbxo4-cyclin D1 axis occurs at high frequency in esophageal squamous cell carcinoma (ESCC), where it promotes ESCC development and progression."7.91Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. ( Bass, AJ; Beeson, CC; Beeson, GC; Diehl, JA; Ogretmen, B; Oleinik, N; Parnham, S; Qie, S; Rustgi, AK; Wong, KK; Yoshida, A, 2019)
"This study aimed at investigating the effects of metformin on the growth and metastasis of esophageal squamous cell carcinoma (ESCC) in vitro and in vivo."7.88Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo. ( Liang, F; Wang, C; Wang, YG, 2018)
"5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%."7.88Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018)
" We have previously shown that the anti-diabetic drug metformin is anti-proliferative and induces an intracellular reducing environment in oesophageal squamous cell carcinoma (OSCC) cell lines."7.81Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines. ( Birkhead, M; Damelin, LH; Jivan, R; Mavri-Damelin, D; Rousseau, AL; Veale, RB, 2015)
"Two hundred eighty-five patients with esophageal adenocarcinoma treated with concurrent chemoradiation (CRT) followed by esophagectomy from 1997 to 2012 were included in the study, including 29 diabetics taking metformin, 21 diabetics not taking metformin and 235 non-diabetics."7.79Metformin use and improved response to therapy in esophageal adenocarcinoma. ( Ajani, JA; Cox, JD; Echeverria, AE; Guerrero, TM; Hofstetter, WL; Komaki, R; Lin, SH; McCurdy, MR; Myers, JN; O'Reilly, MS; Sandulache, VC; Skinner, HD; Welsh, JW, 2013)
"Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer and new treatment strategy is required."5.72Metformin-Induced Heat Shock Protein Family A Member 6 Is a Promising Biomarker of Esophageal Squamous Cell Carcinoma. ( Endo, S; Hirasawa, S; Iida, K; Kamata, T; Kano, M; Kinoshita, K; Kobayashi, S; Komatsu, A; Matsubara, H; Matsumoto, Y; Murakami, K; Okada, K; Otsuka, R; Ryuzaki, T; Sakata, H; Sasaki, T; Sekino, N; Shiraishi, T; Suito, H; Takahashi, M; Toyozumi, T; Yokoyama, M, 2022)
"To stimulate EC carcinogenesis, chronic gastroduodenal reflux esophagitis via esophagojejunostomy was induced in 120 rats in metformin-treated and non-treated (control) groups."5.72Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis. ( Fushida, S; Harashima, A; Inaki, N; Miyashita, T; Munesue, S; Ninomiya, I; Ohta, T; Tajima, H; Takada, S; Takamura, H; Takei, R; Yagi, S; Yamamoto, Y, 2022)
"Treatment of metformin led to activation of AMP-activated protein kinase (AMPK) and attenuated signaling of the downstream molecules such as p-mTOR, p-p70S6K and cyclin D1 expression both in vivo and in vitro."5.51Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway. ( Deng, X; Fan, H; Guo, L; Jiang, W; Lu, SH; Yu, X; Zhan, Q; Zheng, W; Zou, Z, 2019)
"Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer that has proven difficult to treat despite multidisciplinary therapy, and a new treatment strategy is demanded."5.48Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma. ( Akimoto, AK; Akutsu, Y; Hanari, N; Hoshino, I; Iida, K; Kano, M; Matsubara, H; Matsumoto, Y; Murakami, K; Okada, K; Otsuka, R; Sakata, H; Sekino, N; Shiraishi, T; Takahashi, M; Toyozumi, T; Yokoyama, M, 2018)
"Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with poor prognosis in China."5.46Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin. ( Chi, Y; Ding, X; Fan, Q; Lv, Z; Shan, Z; Wang, F; Wang, J; Wang, L; Wang, T; Wu, S; Zhang, Y, 2017)
"Treatment with metformin of athymic nude mice bearing xenograft tumors reduced tumor proliferation."5.42Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. ( Chiyo, T; Fujihara, S; Iwama, H; Kato, K; Kobara, H; Kobayashi, M; Masaki, T; Miyoshi, H; Mori, H; Morishita, A; Nishioka, T; Nishiyama, N; Okano, K; Suzuki, Y, 2015)
"Patients with diagnoses of Barrett esophagus and esophageal cancer were identified during a 20-year period."5.40Metformin use and the risk of esophageal cancer in Barrett esophagus. ( Agrawal, A; Agrawal, S; Deidrich, W; Makhijani, N; Markert, R; Patel, P, 2014)
" The antidiabetic agent metformin may influence anticancer immunity in esophageal squamous cell carcinoma (ESCC)."5.34Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial. ( Bremer, E; Chen, H; Chen, S; Chen, Y; Guo, Y; Lin, P; Lin, Y; Wang, G; Wang, L; Wang, S; Xiong, X; Yeung, SJ; Zhang, H, 2020)
" A large prospective study is expected to elucidate the specific risk of the 90% subtype of esophageal cancer, esophageal squamous cell carcinoma (ESCC), with metformin therapy."3.96Association Between Metformin Use and Risk of Esophageal Squamous Cell Carcinoma in a Population-Based Cohort Study. ( Lagergren, J; Ness-Jensen, E; Santoni, G; Wang, QL; Xie, SH, 2020)
"The dysregulation of Fbxo4-cyclin D1 axis occurs at high frequency in esophageal squamous cell carcinoma (ESCC), where it promotes ESCC development and progression."3.91Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. ( Bass, AJ; Beeson, CC; Beeson, GC; Diehl, JA; Ogretmen, B; Oleinik, N; Parnham, S; Qie, S; Rustgi, AK; Wong, KK; Yoshida, A, 2019)
" In this study, we demonstrated in vitro and in vivo that metformin can induce pyroptosis, a non-apoptotic PCD, in esophageal squamous cell carcinoma (ESCC), a commonly known chemo-refractory cancer, especially at its advanced stages."3.91Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis. ( Chen, Y; Jiang, Y; Li, K; Lin, X; Liu, D; Ning, Z; Wang, J; Wang, L; Wang, S; Xiong, X; Xu, X; Yao, Z; Zhang, D; Zhang, H, 2019)
"5-Fluorouracil (5-FU) is a chemotherapeutic agent used to treat a variety of gastric cancers including oesophageal squamous cell carcinoma (OSCC), for which the 5-year mortality rate exceeds 85%."3.88Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Mynhardt, C; Peres, J; Prince, S; Veale, RB, 2018)
"This study aimed at investigating the effects of metformin on the growth and metastasis of esophageal squamous cell carcinoma (ESCC) in vitro and in vivo."3.88Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo. ( Liang, F; Wang, C; Wang, YG, 2018)
" We have previously shown that the anti-diabetic drug metformin is anti-proliferative and induces an intracellular reducing environment in oesophageal squamous cell carcinoma (OSCC) cell lines."3.81Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines. ( Birkhead, M; Damelin, LH; Jivan, R; Mavri-Damelin, D; Rousseau, AL; Veale, RB, 2015)
"Our clinical study indicates esophageal adenocarcinoma patients on metformin had a better treatment response than those without metformin."3.80Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer. ( Ajani, JA; Chen, Q; Honjo, S; Johnson, RL; Scott, AW; Skinner, HD; Song, S; Stroehlein, J, 2014)
"Two hundred eighty-five patients with esophageal adenocarcinoma treated with concurrent chemoradiation (CRT) followed by esophagectomy from 1997 to 2012 were included in the study, including 29 diabetics taking metformin, 21 diabetics not taking metformin and 235 non-diabetics."3.79Metformin use and improved response to therapy in esophageal adenocarcinoma. ( Ajani, JA; Cox, JD; Echeverria, AE; Guerrero, TM; Hofstetter, WL; Komaki, R; Lin, SH; McCurdy, MR; Myers, JN; O'Reilly, MS; Sandulache, VC; Skinner, HD; Welsh, JW, 2013)
"Metformin has been reported to be associated with improved cancer prognosis when used in combination with chemotherapy and/or radiotherapy."2.82Association of Tumor Pathological Response with the Use of Metformin During Neoadjuvant Chemoradiotherapy in Rectal and Esophageal/Gastroesophageal Cancer Patients: a Systematic Review and Meta-analysis. ( Kitagawa, Y; Matsui, S; Okabayashi, K; Sakamoto, K; Seishima, R; Shigeta, K, 2022)
"Metformin use was associated with reduced risk of OC (HR=0."2.82Is metformin use associated with a reduced risk of oesophageal cancer? A systematic review and meta-analysis. ( Bhan, C; Chen, Y; Cheng, C; Cheng, X; Hu, L; Kailas, S; Karadsheh, Z; Kim, KY; Kim, NH; Manem, R; Qureshi, F; Sun, C; Wu, Y; Zhou, Q; Zhou, Z, 2022)
"Metformin was associated with an almost significant reduction in serum levels of insulin (median -4."2.80Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus. ( Buttar, NS; Chak, A; Cruz-Correa, MR; Falk, GW; Foster, NR; Hur, C; Katzka, DA; Limburg, PJ; Mandrekar, SJ; Marcon, NE; Richmond, E; Rodriguez, LM; Schoen, R; Seisler, DK; Sharma, AN; Sharma, P; Smyrk, TC, 2015)
"Candidates for chemoprevention in Barrett's esophagus have long been suggested and there has been observational data to support many drugs, including statins, hormone replacement therapy, metformin, proton pump inhibitor therapy, and aspirin."2.72Current Status of Chemoprevention in Barrett's Esophagus. ( El-Serag, HB; Moayyedi, P, 2021)
"However, a significant reduction in esophageal cancer risk in Asian populations remains to be clarified."2.72The effect of metformin on esophageal cancer risk in patients with type 2 diabetes mellitus: a systematic review and meta‑analysis. ( Wu, HD; Zhang, JJ; Zhou, BJ, 2021)
"Chemoprevention in Barrett's esophagus is currently applied only in research settings."2.52Chemoprevention in Barrett's Esophagus: Current Status. ( Baruah, A; Buttar, NS; Kossak, SK; Zeb, MH, 2015)
"Among 4851 esophageal cancer patients (8404 person-years), 4072 (84%) died during follow-up."1.91Diabetes, metformin use, and survival in esophageal cancer: a population-based cohort study. ( Lagergren, J; Santoni, G; Wang, QL, 2023)
"To stimulate EC carcinogenesis, chronic gastroduodenal reflux esophagitis via esophagojejunostomy was induced in 120 rats in metformin-treated and non-treated (control) groups."1.72Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis. ( Fushida, S; Harashima, A; Inaki, N; Miyashita, T; Munesue, S; Ninomiya, I; Ohta, T; Tajima, H; Takada, S; Takamura, H; Takei, R; Yagi, S; Yamamoto, Y, 2022)
"The association of oesophageal cancer with drug use and clinical factors was evaluated."1.72Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study. ( Arai, J; Arai, M; Hasatani, K; Hayakawa, Y; Honda, T; Ikeya, T; Kawahara, T; Kawai, T; Kiyotoki, S; Koike, K; Niikura, R; Nishida, T; Sumiyoshi, T; Suzuki, N; Tsuji, Y; Yamada, A; Yoshida, N, 2022)
"Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer and new treatment strategy is required."1.72Metformin-Induced Heat Shock Protein Family A Member 6 Is a Promising Biomarker of Esophageal Squamous Cell Carcinoma. ( Endo, S; Hirasawa, S; Iida, K; Kamata, T; Kano, M; Kinoshita, K; Kobayashi, S; Komatsu, A; Matsubara, H; Matsumoto, Y; Murakami, K; Okada, K; Otsuka, R; Ryuzaki, T; Sakata, H; Sasaki, T; Sekino, N; Shiraishi, T; Suito, H; Takahashi, M; Toyozumi, T; Yokoyama, M, 2022)
" Tissue and breath concentrations of the medium-chain alkanal decanal are correlated, and increased decanal is linked to reduced ALDH3A2 expression, TP53 deletion, and adverse clinical features."1.62Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma. ( Adam, ME; Antonowicz, S; Bodai, Z; Boshier, PR; Fitzgerald, RC; Gabra, H; Goh, YM; Goldin, R; Green, CM; Habib, N; Hanna, GB; Kudo, H; Lu, H; Markar, SR; Moralli, D; Peters, CJ; Rosini, F; Takats, Z; Wiggins, T, 2021)
" Chronic use of other common drugs, namely, statins nonsteroidal anti-inflammatory drugs (NSAIDs) and metformin, may also interfere with BE carcinogenesis, but confirmatory evidence is lacking."1.62Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis. ( Chaloux, M; Loomans-Kropp, HA; Richmond, E; Umar, A, 2021)
"Metformin has different functional roles on the apoptosis in esophageal carcinoma cells and normal esophageal cells."1.56Metformin's Effects on Apoptosis of Esophageal Carcinoma Cells and Normal Esophageal Epithelial Cells: An In Vitro Comparative Study. ( Cai, X; Hong, D; Hu, H; Hu, X; Jing, X; Peng, J; Wang, Q; Wu, J, 2020)
"Treatment of metformin led to activation of AMP-activated protein kinase (AMPK) and attenuated signaling of the downstream molecules such as p-mTOR, p-p70S6K and cyclin D1 expression both in vivo and in vitro."1.51Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway. ( Deng, X; Fan, H; Guo, L; Jiang, W; Lu, SH; Yu, X; Zhan, Q; Zheng, W; Zou, Z, 2019)
"Esophageal squamous cell carcinoma (ESCC) is an intractable digestive organ cancer that has proven difficult to treat despite multidisciplinary therapy, and a new treatment strategy is demanded."1.48Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma. ( Akimoto, AK; Akutsu, Y; Hanari, N; Hoshino, I; Iida, K; Kano, M; Matsubara, H; Matsumoto, Y; Murakami, K; Okada, K; Otsuka, R; Sakata, H; Sekino, N; Shiraishi, T; Takahashi, M; Toyozumi, T; Yokoyama, M, 2018)
"Oesophageal squamous cell carcinoma (OSCC) is highly prevalent in developing countries but there has been little recent progress into efficacious yet affordable treatment strategies."1.48Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo. ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Peres, J; Prince, S; Veale, RB; Wadee, R, 2018)
"Esophageal squamous cell carcinoma (ESCC) is an aggressive malignancy with poor prognosis in China."1.46Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin. ( Chi, Y; Ding, X; Fan, Q; Lv, Z; Shan, Z; Wang, F; Wang, J; Wang, L; Wang, T; Wu, S; Zhang, Y, 2017)
"Metformin restrained esophageal cancer cell proliferation partly by suppressing the PI3K/AKT/mTOR pathway."1.46Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells ( An, R; Jiang, YQ; Tang, JC; Yang, J, 2017)
"Patients with type 2 diabetes mellitus diagnosed during 1999-2005 were recruited from the reimbursement database of Taiwan's National Health Insurance."1.46Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus. ( Tseng, CH, 2017)
"BE subjects developing esophageal cancer (EC) 12 months after their index BE diagnosis were defined as progressors."1.43Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort. ( Borah, B; Chak, A; Das, A; Heien, H; Iyer, PG; Krishnamoorthi, R, 2016)
"Esophageal cancer is one of the most aggressive tumor types because of its invasiveness and metastatic potential."1.43Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma. ( Fushida, S; Harada, S; Hayashi, H; Kinoshita, J; Makino, I; Miyashita, T; Nakanuma, S; Nakayama, A; Ninomiya, I; Ohta, T; Okamoto, K; Oyama, K; Sakai, S; Tajima, H; Takamura, H; Tsukada, T, 2016)
"Esophageal squamous cell carcinomas (ESCC) have become a severe threat to health and the current treatments for ESCC are frequently not effective."1.42Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo. ( Cai, X; Chen, C; Chen, X; Cheng, W; Guan, Y; Hu, X; Jing, X; Tan, X; Wang, Q, 2015)
"Treatment with metformin of athymic nude mice bearing xenograft tumors reduced tumor proliferation."1.42Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. ( Chiyo, T; Fujihara, S; Iwama, H; Kato, K; Kobara, H; Kobayashi, M; Masaki, T; Miyoshi, H; Mori, H; Morishita, A; Nishioka, T; Nishiyama, N; Okano, K; Suzuki, Y, 2015)
"Metformin use has been associated with a dose-dependent increased response to neoadjuvant chemo(radio)therapy in esophageal cancer patients."1.42Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes. ( Anderegg, MC; Gisbertz, SS; Hulshof, MC; Lagarde, SM; Meijer, SL; Spierings, LE; van Berge Henegouwen, MI; van Laarhoven, HW; van Oijen, MG; Wilmink, JW, 2015)
"Oesophageal squamous cell carcinoma (OSCC) is a highly aggressive carcinoma with a poor survival rate."1.40Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones). ( Damelin, LH; Jivan, R; Mavri-Damelin, D; Rousseau, AL; Veale, RB, 2014)
"Patients with diagnoses of Barrett esophagus and esophageal cancer were identified during a 20-year period."1.40Metformin use and the risk of esophageal cancer in Barrett esophagus. ( Agrawal, A; Agrawal, S; Deidrich, W; Makhijani, N; Markert, R; Patel, P, 2014)
"Treatment with metformin was also associated with activation of AMP kinase and inhibition of mTOR/p70S6K/pS6 signaling in both cells."1.39Metformin inhibits esophagus cancer proliferation through upregulation of USP7. ( Lu, S; Xu, Y, 2013)

Research

Studies (46)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's31 (67.39)24.3611
2020's15 (32.61)2.80

Authors

AuthorsStudies
Arai, J1
Niikura, R1
Hayakawa, Y1
Kawahara, T1
Honda, T1
Hasatani, K1
Yoshida, N1
Nishida, T1
Sumiyoshi, T1
Kiyotoki, S1
Ikeya, T1
Arai, M1
Suzuki, N1
Tsuji, Y1
Yamada, A1
Kawai, T1
Koike, K1
Sekino, N2
Kano, M2
Kobayashi, S1
Murakami, K3
Sakata, H2
Toyozumi, T3
Endo, S1
Matsumoto, Y2
Suito, H2
Takahashi, M3
Otsuka, R2
Yokoyama, M2
Shiraishi, T2
Okada, K2
Kamata, T1
Ryuzaki, T1
Hirasawa, S1
Kinoshita, K1
Sasaki, T1
Iida, K2
Komatsu, A1
Matsubara, H3
Sakamoto, K1
Okabayashi, K1
Matsui, S1
Seishima, R1
Shigeta, K1
Kitagawa, Y1
Chen, Y6
Cheng, X1
Sun, C1
Kim, NH1
Kailas, S1
Qureshi, F1
Karadsheh, Z1
Wu, Y2
Hu, L1
Zhou, Z1
Bhan, C1
Kim, KY1
Manem, R1
Cheng, C1
Zhou, Q1
Wang, QL2
Santoni, G2
Lagergren, J2
Li, H6
Zhang, L3
Yang, F1
Zhao, R1
Li, X11
Ness-Jensen, E1
Xie, SH1
Peng, J1
Jing, X2
Wu, J2
Hong, D1
Hu, X3
Wang, Q4
Hu, H1
Cai, X3
Wu, HD1
Zhang, JJ1
Zhou, BJ1
Wang, S4
Lin, Y1
Xiong, X2
Wang, L4
Guo, Y1
Chen, S3
Wang, G1
Lin, P1
Chen, H2
Yeung, SJ1
Bremer, E1
Zhang, H4
Nguépy Keubo, FR1
Mboua, PC1
Djifack Tadongfack, T1
Fokouong Tchoffo, E1
Tasson Tatang, C1
Ide Zeuna, J1
Noupoue, EM1
Tsoplifack, CB1
Folefack, GO1
Kettani, M1
Bandelier, P1
Huo, J1
Yu, D1
Arulsamy, N1
AlAbbad, S1
Sardot, T1
Lekashvili, O1
Decato, D1
Lelj, F1
Alexander Ross, JB1
Rosenberg, E1
Nazir, H1
Muthuswamy, N1
Louis, C1
Jose, S1
Prakash, J1
Buan, MEM1
Flox, C1
Chavan, S1
Shi, X1
Kauranen, P1
Kallio, T1
Maia, G1
Tammeveski, K1
Lymperopoulos, N1
Carcadea, E1
Veziroglu, E1
Iranzo, A1
M Kannan, A1
Arunamata, A1
Tacy, TA1
Kache, S1
Mainwaring, RD1
Ma, M1
Maeda, K1
Punn, R1
Noguchi, S1
Hahn, S3
Iwasa, Y3
Ling, J2
Voccio, JP2
Kim, Y3
Song, J3
Bascuñán, J2
Chu, Y1
Tomita, M1
Cazorla, M1
Herrera, E1
Palomeque, E1
Saud, N1
Hoplock, LB1
Lobchuk, MM1
Lemoine, J1
Henson, MA1
Unsihuay, D1
Qiu, J1
Swaroop, S1
Nagornov, KO1
Kozhinov, AN1
Tsybin, YO1
Kuang, S1
Laskin, J1
Zin, NNINM1
Mohamad, MN1
Roslan, K1
Abdul Wafi, S1
Abdul Moin, NI1
Alias, A1
Zakaria, Y1
Abu-Bakar, N1
Naveed, A1
Jilani, K1
Siddique, AB1
Akbar, M1
Riaz, M1
Mushtaq, Z1
Sikandar, M1
Ilyas, S1
Bibi, I1
Asghar, A1
Rasool, G1
Irfan, M1
Li, XY1
Zhao, S1
Fan, XH1
Chen, KP1
Hua, W1
Liu, ZM1
Xue, XD1
Zhou, B1
Zhang, S2
Xing, YL1
Chen, MA1
Sun, Y1
Neradilek, MB1
Wu, XT1
Zhang, D3
Huang, W1
Cui, Y1
Yang, QQ1
Li, HW1
Zhao, XQ1
Hossein Rashidi, B1
Tarafdari, A1
Ghazimirsaeed, ST1
Shahrokh Tehraninezhad, E1
Keikha, F1
Eslami, B1
Ghazimirsaeed, SM1
Jafarabadi, M1
Silvani, Y1
Lovita, AND1
Maharani, A1
Wiyasa, IWA1
Sujuti, H1
Ratnawati, R1
Raras, TYM1
Lemin, AS1
Rahman, MM1
Pangarah, CA1
Kiyu, A1
Zeng, C2
Du, H1
Lin, D1
Jalan, D1
Rubagumya, F1
Hopman, WM1
Vanderpuye, V1
Lopes, G1
Seruga, B1
Booth, CM1
Berry, S1
Hammad, N1
Sajo, EA1
Okunade, KS1
Olorunfemi, G1
Rabiu, KA1
Anorlu, RI1
Xu, C2
Xiang, Y1
Xu, X2
Zhou, L2
Dong, X1
Tang, S1
Gao, XC1
Wei, CH1
Zhang, RG1
Cai, Q1
He, Y1
Tong, F1
Dong, JH1
Wu, G1
Dong, XR1
Tang, X1
Tao, F1
Xiang, W1
Zhao, Y2
Jin, L1
Tao, H1
Lei, Y1
Gan, H1
Huang, Y1
Chen, L3
Shan, A1
Zhao, H2
Wu, M2
Ma, Q1
Wang, J6
Zhang, E1
Zhang, J3
Li, Y5
Xue, F1
Deng, L1
Liu, L2
Yan, Z2
Wang, Y2
Meng, J1
Chen, G2
Anastassiadou, M1
Bernasconi, G1
Brancato, A1
Carrasco Cabrera, L1
Greco, L1
Jarrah, S1
Kazocina, A1
Leuschner, R1
Magrans, JO1
Miron, I1
Nave, S1
Pedersen, R1
Reich, H1
Rojas, A1
Sacchi, A1
Santos, M1
Theobald, A1
Vagenende, B1
Verani, A1
Du, L1
Liu, X1
Ren, Y1
Li, J7
Li, P1
Jiao, Q1
Meng, P1
Wang, F3
Wang, YS1
Wang, C4
Zhou, X2
Wang, W1
Hou, J1
Zhang, A1
Lv, B1
Gao, C1
Pang, D1
Lu, K1
Ahmad, NH1
Zhu, J2
Zhuang, T1
Tu, J1
Zhao, Z1
Qu, Y1
Yao, H1
Wang, X5
Lee, DF1
Shen, J3
Wen, L1
Huang, G2
Xie, X1
Zhao, Q1
Hu, W1
Zhang, Y5
Wu, X1
Lu, J2
Li, M1
Li, W2
Wu, W1
Du, F1
Ji, H1
Yang, X2
Xu, Z1
Wan, L1
Wen, Q1
Cho, CH1
Zou, C1
Xiao, Z1
Liao, J1
Su, X1
Bi, Z1
Su, Q1
Huang, H1
Wei, Y2
Gao, Y2
Na, KJ1
Choi, H1
Oh, HR1
Kim, YH1
Lee, SB1
Jung, YJ1
Koh, J1
Park, S1
Lee, HJ1
Jeon, YK1
Chung, DH1
Paeng, JC1
Park, IK1
Kang, CH1
Cheon, GJ1
Kang, KW1
Lee, DS1
Kim, YT1
Pajuelo-Lozano, N1
Alcalá, S1
Sainz, B1
Perona, R1
Sanchez-Perez, I1
Logotheti, S1
Marquardt, S1
Gupta, SK1
Richter, C1
Edelhäuser, BAH1
Engelmann, D1
Brenmoehl, J1
Söhnchen, C1
Murr, N1
Alpers, M1
Singh, KP1
Wolkenhauer, O1
Heckl, D1
Spitschak, A1
Pützer, BM1
Liao, Y1
Cheng, J1
Kong, X1
Li, S1
Zhang, M4
Yang, T2
Dong, Y1
Xu, Y2
Yuan, Z1
Cao, J1
Zheng, Y1
Luo, Z1
Mei, Z1
Yao, Y1
Liu, Z2
Liang, C1
Yang, H1
Song, Y1
Yu, K1
Zhu, C1
Huang, Z1
Qian, J1
Ge, J1
Hu, J2
Wang, H2
Liu, Y4
Mi, Y1
Kong, H1
Xi, D1
Yan, W1
Luo, X1
Ning, Q1
Chang, X2
Zhang, T2
Rathore, MG1
Reddy, K1
Shin, SH1
Ma, WY1
Bode, AM1
Dong, Z1
Mu, W1
Liu, C3
Gao, F1
Qi, Y1
Lu, H2
Zhang, X4
Ji, RY1
Hou, Y3
Tian, J2
Shi, Y1
Ying, S1
Tan, M1
Feng, G1
Kuang, Y1
Chen, D1
Wu, D3
Zhu, ZQ1
Tang, HX1
Shi, ZE1
Kang, J1
Liu, Q1
Qi, J2
Mu, J1
Cong, Z1
Fu, D1
Li, Z2
Celestrin, CP1
Rocha, GZ1
Stein, AM1
Guadagnini, D1
Tadelle, RM1
Saad, MJA1
Oliveira, AG1
Bianconi, V1
Bronzo, P1
Banach, M1
Sahebkar, A1
Mannarino, MR1
Pirro, M1
Patsourakos, NG1
Kouvari, M1
Kotidis, A1
Kalantzi, KI1
Tsoumani, ME1
Anastasiadis, F1
Andronikos, P1
Aslanidou, T1
Efraimidis, P1
Georgiopoulos, A1
Gerakiou, K1
Grigoriadou-Skouta, E1
Grigoropoulos, P1
Hatzopoulos, D1
Kartalis, A1
Lyras, A1
Markatos, G1
Mikrogeorgiou, A1
Myroforou, I1
Orkopoulos, A1
Pavlidis, P1
Petras, C1
Riga, M1
Skouloudi, M1
Smyrnioudis, N1
Thomaidis, K1
Tsikouri, GE1
Tsikouris, EI1
Zisimos, K1
Vavoulis, P1
Vitali, MG1
Vitsas, G1
Vogiatzidis, C1
Chantanis, S1
Fousas, S1
Panagiotakos, DB1
Tselepis, AD1
Jungen, C1
Alken, FA1
Eickholt, C1
Scherschel, K1
Kuklik, P1
Klatt, N1
Schwarzl, J1
Moser, J1
Jularic, M1
Akbulak, RO1
Schaeffer, B1
Willems, S1
Meyer, C1
Nowak, JK1
Szczepanik, M1
Trypuć, M1
Pogorzelski, A1
Bobkowski, W1
Grytczuk, M1
Minarowska, A1
Wójciak, R1
Walkowiak, J1
Lu, Y1
Xi, J1
Li, C1
Chen, W2
Zhang, F1
Wei, H1
Wang, Z1
Gurzu, S1
Jung, I1
Sugimura, H2
Stefan-van Staden, RI1
Yamada, H1
Natsume, H1
Iwashita, Y1
Szodorai, R1
Szederjesi, J1
Yari, D1
Ehsanbakhsh, Z1
Validad, MH1
Langroudi, FH1
Esfandiari, H1
Prager, A1
Hassanpour, K1
Kurup, SP1
Mets-Halgrimson, R1
Yoon, H1
Zeid, JL1
Mets, MB1
Rahmani, B1
Araujo-Castillo, RV1
Culquichicón, C1
Solis Condor, R1
Efendi, F1
Sebayang, SK1
Astutik, E1
Hadisuyatmana, S1
Has, EMM1
Kuswanto, H1
Foroutan, T1
Ahmadi, F1
Moayer, F1
Khalvati, S1
Zhang, Q2
Lyu, Y1
Huang, J2
Yu, N1
Wen, Z1
Hou, H1
Zhao, T1
Gupta, A1
Khosla, N1
Govindasamy, V1
Saini, A1
Annapurna, K1
Dhakate, SR1
Akkaya, Ö1
Chandgude, AL1
Dömling, A1
Harnett, J1
Oakes, K1
Carè, J1
Leach, M1
Brown, D1
Cramer, H1
Pinder, TA1
Steel, A1
Anheyer, D1
Cantu, J1
Valle, J1
Flores, K1
Gonzalez, D1
Valdes, C1
Lopez, J1
Padilla, V1
Alcoutlabi, M1
Parsons, J1
Núñez, K1
Hamed, M1
Fort, D1
Bruce, D1
Thevenot, P1
Cohen, A1
Weber, P1
Menezes, AMB1
Gonçalves, H1
Perez-Padilla, R1
Jarvis, D1
de Oliveira, PD1
Wehrmeister, FC1
Mir, S1
Wong, J1
Ryan, CM1
Bellingham, G1
Singh, M2
Waseem, R1
Eckert, DJ1
Chung, F1
Hegde, H1
Shimpi, N1
Panny, A1
Glurich, I1
Christie, P1
Acharya, A1
English, KL1
Downs, M1
Goetchius, E1
Buxton, R1
Ryder, JW1
Ploutz-Snyder, R1
Guilliams, M1
Scott, JM1
Ploutz-Snyder, LL1
Martens, C1
Goplen, FK1
Aasen, T1
Gjestad, R1
Nordfalk, KF1
Nordahl, SHG1
Inoue, T1
Soshi, S1
Kubota, M1
Marumo, K1
Mortensen, NP1
Caffaro, MM1
Patel, PR2
Uddin, MJ1
Aravamudhan, S1
Sumner, SJ1
Fennell, TR1
Gal, RL1
Cohen, NJ1
Kruger, D1
Beck, RW1
Bergenstal, RM1
Calhoun, P1
Cushman, T1
Haban, A1
Hood, K1
Johnson, ML1
McArthur, T1
Olson, BA1
Weinstock, RS1
Oser, SM1
Oser, TK1
Bugielski, B1
Strayer, H1
Aleppo, G1
Maruyama, H1
Hirayama, K1
Yamashita, M1
Ohgi, K1
Tsujimoto, R1
Takayasu, M1
Shimohata, H1
Kobayashi, M3
Buscagan, TM1
Rees, DC1
Jaborek, JR1
Zerby, HN1
Wick, MP1
Fluharty, FL1
Moeller, SJ1
Razavi, P1
Dickler, MN1
Shah, PD1
Toy, W1
Brown, DN1
Won, HH1
Li, BT1
Shen, R1
Vasan, N1
Modi, S1
Jhaveri, K1
Caravella, BA1
Patil, S1
Selenica, P1
Zamora, S1
Cowan, AM1
Comen, E1
Singh, A1
Covey, A1
Berger, MF1
Hudis, CA1
Norton, L1
Nagy, RJ1
Odegaard, JI1
Lanman, RB1
Solit, DB1
Robson, ME1
Lacouture, ME1
Brogi, E1
Reis-Filho, JS1
Moynahan, ME1
Scaltriti, M1
Chandarlapaty, S1
Papouskova, K1
Moravcova, M1
Masrati, G1
Ben-Tal, N1
Sychrova, H1
Zimmermannova, O1
Fang, J1
Fan, Y1
Luo, T2
Su, H1
Tsetseris, L1
Anthopoulos, TD1
Liu, SF1
Zhao, K1
Sacan, O1
Turkyilmaz, IB1
Bayrak, BB1
Mutlu, O1
Akev, N1
Yanardag, R1
Gruber, S1
Kamnoedboon, P1
Özcan, M1
Srinivasan, M1
Jo, YH1
Oh, HK1
Jeong, SY1
Lee, BG1
Zheng, J1
Guan, H1
Li, D2
Tan, H1
Maji, TK1
J R, A1
Mukherjee, S1
Alexander, R1
Mondal, A1
Das, S1
Sharma, RK1
Chakraborty, NK1
Dasgupta, K1
Sharma, AMR1
Hawaldar, R1
Pandey, M1
Naik, A1
Majumdar, K1
Pal, SK1
Adarsh, KV1
Ray, SK1
Karmakar, D1
Ma, Y2
Gao, W1
Ma, S1
Lin, W2
Zhou, T1
Wu, T1
Wu, Q1
Ye, C1
He, X2
Jiang, F1
Yuan, D1
Chen, Q2
Hong, M1
Chen, K1
Hussain, M1
Razi, SS1
Yildiz, EA1
Zhao, J1
Yaglioglu, HG1
Donato, MD1
Jiang, J1
Jamil, MI1
Zhan, X1
Chen, F1
Cheng, D1
Wu, CT1
Utsunomiya, T1
Ichii, T1
Fujinami, S1
Nakajima, K1
Sanchez, DM1
Raucci, U1
Ferreras, KN1
Martínez, TJ1
Mordi, NA1
Mordi, IR1
Singh, JS1
McCrimmon, RJ1
Struthers, AD1
Lang, CC1
Wang, XW1
Yuan, LJ1
Yang, Y1
Chen, WF1
Luo, R1
Yang, K1
Amarasiri, SS1
Attanayake, AP1
Arawwawala, LDAM1
Jayatilaka, KAPW1
Mudduwa, LKB1
Ogunsuyi, O2
Akanni, O1
Alabi, O1
Alimba, C1
Adaramoye, O1
Cambier, S1
Eswara, S1
Gutleb, AC1
Bakare, A1
Gu, Z1
Cong, J1
Pellegrini, M1
Palmieri, S1
Ricci, A1
Serio, A1
Paparella, A1
Lo Sterzo, C1
Jadeja, SD1
Vaishnav, J1
Mansuri, MS1
Shah, C1
Mayatra, JM1
Shah, A1
Begum, R1
Song, H2
Lian, Y1
Wan, T1
Schultz-Lebahn, A1
Skipper, MT1
Hvas, AM1
Larsen, OH1
Hijazi, Z1
Granger, CB1
Hohnloser, SH1
Westerbergh, J1
Lindbäck, J1
Alexander, JH1
Keltai, M1
Parkhomenko, A1
López-Sendón, JL1
Lopes, RD1
Siegbahn, A1
Wallentin, L1
El-Tarabany, MS1
Saleh, AA1
El-Araby, IE1
El-Magd, MA1
van Ginkel, MPH1
Schijven, MP1
van Grevenstein, WMU1
Schreuder, HWR1
Pereira, EDM1
da Silva, J1
Carvalho, PDS1
Grivicich, I1
Picada, JN1
Salgado Júnior, IB1
Vasques, GJ1
Pereira, MADS1
Reginatto, FH1
Ferraz, ABF1
Vasilenko, EA1
Gorshkova, EN1
Astrakhantseva, IV1
Drutskaya, MS1
Tillib, SV1
Nedospasov, SA1
Mokhonov, VV1
Nam, YW1
Cui, M1
Orfali, R1
Viegas, A1
Nguyen, M1
Mohammed, EHM1
Zoghebi, KA1
Rahighi, S1
Parang, K1
Patterson, KC1
Kahanovitch, U1
Gonçalves, CM1
Hablitz, JJ1
Staruschenko, A1
Mulkey, DK1
Olsen, ML1
Gu, L1
Cao, X1
Mukhtar, A1
Wu, K1
Zhang, YY1
Zhu, Y1
Lu, DZ1
Dong, W1
Bi, WJ1
Feng, XJ1
Wen, LM1
Sun, H1
Qi, MC1
Chang, CC1
Dinh, TK1
Lee, YA1
Wang, FN1
Sung, YC1
Yu, PL1
Chiu, SC1
Shih, YC1
Wu, CY1
Huang, YD1
Lu, TT1
Wan, D1
Sakizadeh, J1
Cline, JP1
Snyder, MA1
Kiely, CJ1
McIntosh, S1
Jiang, X1
Cao, JW1
Zhao, CK1
Yang, R1
Zhang, QY1
Chen, KJ2
Liu, H1
He, Z1
Chen, B1
Du, X1
Moore, J1
Blank, BR1
Eksterowicz, J1
Sutimantanapi, D1
Yuen, N1
Metzger, T1
Chan, B1
Huang, T1
Chen, X2
Duong, F1
Kong, W1
Chang, JH1
Sun, J1
Zavorotinskaya, T1
Ye, Q1
Junttila, MR1
Ndubaku, C1
Friedman, LS1
Fantin, VR1
Sun, D1
Fei, P1
Xie, Q1
Jiang, Y2
Feng, H1
Chang, Y1
Kang, H1
Xing, M1
Chen, J1
Shao, Z1
Yuan, C1
Allan, R1
Canham, K1
Wallace, R1
Singh, D1
Ward, J1
Cooper, A1
Newcomb, C1
Nammour, S1
El Mobadder, M1
Maalouf, E1
Namour, M1
Namour, A1
Rey, G1
Matamba, P1
Matys, J1
Zeinoun, T1
Grzech-Leśniak, K1
Segabinazi Peserico, C1
Garozi, L1
Zagatto, AM1
Machado, FA1
Hirth, JM1
Dinehart, EE1
Lin, YL1
Kuo, YF1
Nouri, SS1
Ritchie, C1
Volow, A1
Li, B2
McSpadden, S1
Dearman, K1
Kotwal, A1
Sudore, RL1
Ward, L1
Thakur, A1
Kondadasula, SV1
Ji, K1
Schalk, DL1
Bliemeister, E1
Ung, J1
Aboukameel, A1
Casarez, E1
Sloane, BF1
Lum, LG1
Xiao, M1
Feng, X1
Gao, R1
Du, B1
Brooks, T1
Zwirner, J1
Hammer, N1
Ondruschka, B1
Jermy, M1
Luengo, A1
Marzo, I1
Reback, M1
Daubit, IM1
Fernández-Moreira, V1
Metzler-Nolte, N1
Gimeno, MC1
Tonchev, I1
Heberman, D1
Peretz, A1
Medvedovsky, AT1
Gotsman, I1
Rashi, Y1
Poles, L1
Goland, S1
Perlman, GY1
Danenberg, HD1
Beeri, R1
Shuvy, M1
Fu, Q1
Yang, D1
Sarapulova, A1
Pang, Q1
Meng, Y1
Wei, L1
Ehrenberg, H1
Kim, CC1
Jeong, SH1
Oh, KH1
Nam, KT1
Sun, JY1
Ning, J1
Duan, Z1
Kershaw, SV1
Rogach, AL1
Gao, Z1
Wang, T2
Li, Q1
Cao, T1
Guo, L2
Fu, Y1
Seeger, ZL1
Izgorodina, EI1
Hue, S1
Beldi-Ferchiou, A1
Bendib, I1
Surenaud, M1
Fourati, S1
Frapard, T1
Rivoal, S1
Razazi, K1
Carteaux, G1
Delfau-Larue, MH1
Mekontso-Dessap, A1
Audureau, E1
de Prost, N1
Gao, SS1
Duangthip, D1
Lo, ECM1
Chu, CH1
Roberts, W1
Rosenheck, RA1
Miyake, T1
Kimoto, E1
Luo, L1
Mathialagan, S1
Horlbogen, LM1
Ramanathan, R1
Wood, LS1
Johnson, JG1
Le, VH1
Vourvahis, M1
Rodrigues, AD1
Muto, C1
Furihata, K1
Sugiyama, Y1
Kusuhara, H1
Gong, Q1
Song, W1
Sun, B1
Cao, P1
Gu, S1
Sun, X1
Zhou, G1
Toma, C1
Khandhar, S1
Zalewski, AM1
D'Auria, SJ1
Tu, TM1
Jaber, WA1
Cho, J2
Suwandaratne, NS1
Razek, S1
Choi, YH1
Piper, LFJ1
Watson, DF1
Banerjee, S1
Xie, S1
Lindsay, AP1
Bates, FS1
Lodge, TP1
Hao, Y1
Chapovetsky, A1
Liu, JJ1
Welborn, M1
Luna, JM1
Do, T1
Haiges, R1
Miller Iii, TF1
Marinescu, SC1
Lopez, SA1
Compter, I1
Eekers, DBP1
Hoeben, A1
Rouschop, KMA1
Reymen, B1
Ackermans, L1
Beckervordersantforth, J1
Bauer, NJC1
Anten, MM1
Wesseling, P1
Postma, AA1
De Ruysscher, D1
Lambin, P2
Qiang, L1
Yang, S1
Cui, YH1
He, YY1
Kumar, SK1
Jacobus, SJ1
Cohen, AD1
Weiss, M1
Callander, N1
Singh, AK1
Parker, TL1
Menter, A1
Parsons, B1
Kumar, P1
Kapoor, P1
Rosenberg, A1
Zonder, JA1
Faber, E1
Lonial, S1
Anderson, KC1
Richardson, PG1
Orlowski, RZ1
Wagner, LI1
Rajkumar, SV1
Li, G1
Hou, G1
Cui, J1
Xie, H1
Sun, Z1
Fang, Z1
Dunstand-Guzmán, E1
Hallal-Calleros, C1
Hernández-Velázquez, VM1
Canales-Vargas, EJ1
Domínguez-Roldan, R1
Pedernera, M1
Peña-Chora, G1
Flores-Pérez, I1
Kim, MJ1
Han, C1
White, K1
Park, HJ1
Ding, D1
Boyd, K1
Rothenberger, C1
Bose, U1
Carmichael, P1
Linser, PJ1
Tanokura, M1
Salvi, R1
Someya, S1
Samuni, A1
Goldstein, S1
Divya, KP1
Dharuman, V1
Feng, J2
Qian, Y1
Cheng, Q1
Ma, H1
Ren, X1
Wei, Q1
Pan, W1
Guo, J1
Situ, B1
An, T1
Zheng, L1
Augusto, S1
Ratola, N1
Tarín-Carrasco, P1
Jiménez-Guerrero, P1
Turco, M1
Schuhmacher, M1
Costa, S1
Teixeira, JP1
Costa, C1
Syed, A1
Marraiki, N1
Al-Rashed, S1
Elgorban, AM1
Yassin, MT1
Chankhanittha, T1
Nanan, S1
Sorokina, KN1
Samoylova, YV1
Gromov, NV1
Ogorodnikova, OL1
Parmon, VN1
Ye, J1
Liao, W1
Zhang, P1
Nabi, M1
Cai, Y1
Li, F1
Alsbou, EM1
Omari, KW1
Adeosun, WA1
Asiri, AM1
Marwani, HM1
Barral, M1
Jemal-Turki, A1
Beuvon, F1
Soyer, P1
Camparo, P1
Cornud, F1
Atwater, BD1
Jones, WS1
Loring, Z1
Friedman, DJ1
Namburath, M1
Papirio, S1
Moscariello, C1
Di Costanzo, N1
Pirozzi, F1
Alappat, BJ1
Sreekrishnan, TR1
Volpin, F1
Woo, YC1
Kim, H1
Freguia, S1
Jeong, N1
Choi, JS1
Phuntsho, S1
Shon, HK1
Domínguez-Zambrano, E1
Pedraza-Chaverri, J1
López-Santos, AL1
Medina-Campos, ON1
Cruz-Rivera, C1
Bueno-Hernández, F1
Espinosa-Cuevas, A1
Bulavaitė, A1
Dalgediene, I1
Michailoviene, V1
Pleckaityte, M1
Sauerbier, P1
Köhler, R1
Renner, G1
Militz, H1
Loomans-Kropp, HA1
Chaloux, M1
Richmond, E2
Umar, A1
Moayyedi, P1
El-Serag, HB1
Antonowicz, S1
Bodai, Z1
Wiggins, T1
Markar, SR1
Boshier, PR1
Goh, YM1
Adam, ME1
Kudo, H1
Rosini, F1
Goldin, R1
Moralli, D1
Green, CM1
Peters, CJ1
Habib, N1
Gabra, H1
Fitzgerald, RC1
Takats, Z1
Hanna, GB1
Takei, R1
Miyashita, T2
Takada, S1
Tajima, H2
Ninomiya, I2
Takamura, H2
Fushida, S2
Harashima, A1
Munesue, S1
Yagi, S1
Inaki, N1
Ohta, T2
Yamamoto, Y1
Ding, X1
Shan, Z1
Wu, S1
Chi, Y1
Lv, Z1
Fan, Q1
Mynhardt, C1
Damelin, LH4
Jivan, R4
Peres, J2
Prince, S2
Veale, RB4
Mavri-Damelin, D4
Wadee, R1
Akutsu, Y2
Hanari, N2
Hoshino, I2
Akimoto, AK1
Fan, H1
Yu, X1
Zou, Z1
Zheng, W1
Deng, X1
Jiang, W1
Zhan, Q1
Lu, SH1
Liang, F1
Wang, YG1
Li, K1
Lin, X1
Yao, Z1
Ning, Z1
Liu, D1
Qie, S1
Yoshida, A1
Parnham, S1
Oleinik, N1
Beeson, GC1
Beeson, CC1
Ogretmen, B1
Bass, AJ1
Wong, KK1
Rustgi, AK1
Diehl, JA1
Liu, CC1
Chou, KT1
Hsu, JW1
Lin, JH1
Hsu, TW1
Yen, DH1
Hung, SC1
Hsu, HS1
Becker, C1
Meier, CR1
Jick, SS1
Bodmer, M1
Lu, S1
Feng, Y1
Ke, C1
Tang, Q1
Dong, H1
Zheng, X1
Ke, J1
Yeung, SC1
Honjo, S1
Ajani, JA2
Scott, AW1
Skinner, HD2
Stroehlein, J1
Johnson, RL1
Song, S1
Rousseau, AL2
Isozaki, Y1
Mori, M1
Nishimori, T1
Akanuma, N1
Takeshita, N1
Maruyama, T1
Suzuki, A1
Nakayama, T1
Chak, A2
Buttar, NS2
Foster, NR1
Seisler, DK1
Marcon, NE1
Schoen, R1
Cruz-Correa, MR1
Falk, GW1
Sharma, P1
Hur, C1
Katzka, DA1
Rodriguez, LM1
Sharma, AN1
Smyrk, TC1
Mandrekar, SJ1
Limburg, PJ1
Agrawal, S1
Patel, P1
Agrawal, A1
Makhijani, N1
Markert, R1
Deidrich, W1
Fujihara, S2
Kato, K2
Morishita, A1
Iwama, H2
Nishioka, T1
Chiyo, T1
Nishiyama, N2
Miyoshi, H2
Kobara, H2
Mori, H2
Okano, K1
Suzuki, Y1
Masaki, T2
He, LR1
Qiao, W1
Liao, ZX1
Komaki, R2
Ho, L1
Hofstetter, WL2
Lin, SH2
Birkhead, M1
Zeb, MH1
Baruah, A1
Kossak, SK1
Van De Voorde, L1
Janssen, L1
Larue, R1
Houben, R1
Buijsen, J1
Sosef, M1
Vanneste, B1
Schraepen, MC1
Berbée, M1
Tan, X1
Cheng, W1
Guan, Y1
Chen, C1
Spierings, LE1
Lagarde, SM1
van Oijen, MG1
Gisbertz, SS1
Wilmink, JW1
Hulshof, MC1
Meijer, SL1
Anderegg, MC1
van Berge Henegouwen, MI1
van Laarhoven, HW1
Krishnamoorthi, R1
Borah, B1
Heien, H1
Das, A1
Iyer, PG1
Yu, H1
Bian, X1
Gu, D1
Nakayama, A1
Harada, S1
Tsukada, T1
Okamoto, K1
Nakanuma, S1
Sakai, S1
Makino, I1
Kinoshita, J1
Hayashi, H1
Oyama, K1
Tang, JC1
An, R1
Jiang, YQ1
Yang, J1
Tseng, CH1
McCurdy, MR1
Echeverria, AE1
Welsh, JW1
O'Reilly, MS1
Cox, JD1
Sandulache, VC1
Myers, JN1
Guerrero, TM1
Mimura, S1
Toyota, Y1
Nomura, T1
Nomura, K1
Tani, J1
Murao, K1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Augmentation of Volatile Biomarkers of Oesophageal and Gastric Adenocarcinoma From the Tumour Lipidome[NCT05600608]100 participants (Anticipated)Interventional2022-11-30Not yet recruiting
Randomized Double Blind Placebo Controlled Trial of Barrett's Esophagus Chemoprevention With Metformin[NCT01447927]Phase 293 participants (Actual)Interventional2012-06-30Completed
The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma[NCT02978547]Phase 220 participants (Anticipated)Interventional2019-01-31Not yet recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus

The percent change in pS6K1 was calculated as month 3 pS6k1 values minus baseline pS6k1 values, then divide by baseline pS6k1 values and multiply by 100. (NCT01447927)
Timeframe: Baseline to 3 months

Interventionpercentage of change (Median)
Metformin1.4
Placebo-14.7

Overall Adverse Event Rates

"Number of patients that experienced adverse events (grade 1 or above) as measured by NCI CTCAE (Common Terminology Criteria for Adverse Events) v. 4.0.~The data reported in the table include only the commonly occurring adverse events (3 or more events)." (NCT01447927)
Timeframe: Up to 30 days

,
Interventionparticipants (Number)
Abdominal PainCoughDiarrheaDyspepsiaFatigueFlatulenceFlu like symptomsGastrointestinal disorders - other, specifyHeadacheNausea
Metformin60102421235
Placebo0353122223

Reviews

7 reviews available for metformin and Esophageal Neoplasms

ArticleYear
Association of Tumor Pathological Response with the Use of Metformin During Neoadjuvant Chemoradiotherapy in Rectal and Esophageal/Gastroesophageal Cancer Patients: a Systematic Review and Meta-analysis.
    Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract, 2022, Volume: 26, Issue:10

    Topics: Adenocarcinoma; Chemoradiotherapy; Esophageal Neoplasms; Humans; Metformin; Neoadjuvant Therapy; Rec

2022
Is metformin use associated with a reduced risk of oesophageal cancer? A systematic review and meta-analysis.
    Postgraduate medical journal, 2022, Nov-01, Volume: 98, Issue:1165

    Topics: Esophageal Neoplasms; Humans; Metformin

2022
Impact of concomitant medications on the efficacy of immune checkpoint inhibitors: an umbrella review.
    Frontiers in immunology, 2023, Volume: 14

    Topics: Analgesics, Opioid; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Esophag

2023
The effect of metformin on esophageal cancer risk in patients with type 2 diabetes mellitus: a systematic review and meta‑analysis.
    Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2021, Volume: 23, Issue:2

    Topics: Asian People; Case-Control Studies; Confidence Intervals; Diabetes Mellitus, Type 2; Esophageal Neop

2021
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Current Status of Chemoprevention in Barrett's Esophagus.
    Gastrointestinal endoscopy clinics of North America, 2021, Volume: 31, Issue:1

    Topics: Adenocarcinoma; Aspirin; Barrett Esophagus; Chemoprevention; Drug Therapy, Combination; Esophageal N

2021
Chemoprevention in Barrett's Esophagus: Current Status.
    Gastroenterology clinics of North America, 2015, Volume: 44, Issue:2

    Topics: Adenocarcinoma; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Bile Acids and Salts; Cy

2015

Trials

3 trials available for metformin and Esophageal Neoplasms

ArticleYear
Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2020, 09-15, Volume: 26, Issue:18

    Topics: Adolescent; Adult; Aged; Animals; Apoptosis; Carcinogens; Cell Line, Tumor; Cell Proliferation; Coho

2020
Psychological distress among health care professionals of the three COVID-19 most affected Regions in Cameroon: Prevalence and associated factors.
    Annales medico-psychologiques, 2021, Volume: 179, Issue:2

    Topics: 3' Untranslated Regions; 5'-Nucleotidase; A549 Cells; Accidental Falls; Acetylcholinesterase; Acryli

2021
Metformin does not reduce markers of cell proliferation in esophageal tissues of patients with Barrett's esophagus.
    Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association, 2015, Volume: 13, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Barrett Esophagus; Cell Proliferation; Double-Blind Method; Endoscop

2015

Other Studies

37 other studies available for metformin and Esophageal Neoplasms

ArticleYear
Chemoprevention of Oesophageal Squamous-Cell Carcinoma and Adenocarcinoma: A Multicentre Retrospective Cohort Study.
    Digestion, 2022, Volume: 103, Issue:3

    Topics: Adenocarcinoma; Aspirin; Case-Control Studies; Chemoprevention; Esophageal Neoplasms; Esophageal Squ

2022
Metformin-Induced Heat Shock Protein Family A Member 6 Is a Promising Biomarker of Esophageal Squamous Cell Carcinoma.
    Oncology, 2022, Volume: 100, Issue:5

    Topics: Biomarkers, Tumor; Carcinoma, Squamous Cell; Cell Line, Tumor; Esophageal Neoplasms; Esophageal Squa

2022
Diabetes, metformin use, and survival in esophageal cancer: a population-based cohort study.
    JNCI cancer spectrum, 2023, 07-03, Volume: 7, Issue:4

    Topics: Cohort Studies; Diabetes Mellitus; Esophageal Neoplasms; Humans; Insulins; Metformin; Risk Factors;

2023
Association Between Metformin Use and Risk of Esophageal Squamous Cell Carcinoma in a Population-Based Cohort Study.
    The American journal of gastroenterology, 2020, Volume: 115, Issue:1

    Topics: Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Female; Follow-Up Studies; Humans; Hypogly

2020
Metformin's Effects on Apoptosis of Esophageal Carcinoma Cells and Normal Esophageal Epithelial Cells: An In Vitro Comparative Study.
    BioMed research international, 2020, Volume: 2020

    Topics: Apoptosis; Cell Line, Tumor; Epithelial Cells; Esophageal Neoplasms; Esophagus; Humans; Metformin

2020
Association of Common Use Pharmaceuticals in Reducing Risk of Esophageal Adenocarcinoma: A SEER-Medicare Analysis.
    Cancer prevention research (Philadelphia, Pa.), 2021, Volume: 14, Issue:2

    Topics: Adenocarcinoma; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus;

2021
Endogenous aldehyde accumulation generates genotoxicity and exhaled biomarkers in esophageal adenocarcinoma.
    Nature communications, 2021, 03-05, Volume: 12, Issue:1

    Topics: Adenocarcinoma; Aldehyde Dehydrogenase; Aldehyde Oxidoreductases; Aldehydes; Biomarkers, Tumor; DNA

2021
Dynamic switch of immunity and antitumor effects of metformin in rat spontaneous esophageal carcinogenesis.
    Cancer immunology, immunotherapy : CII, 2022, Volume: 71, Issue:4

    Topics: Adenocarcinoma; Animals; Barrett Esophagus; Carcinogenesis; Esophageal Neoplasms; Metformin; Rats; T

2022
Metformin inhibited esophageal squamous cell carcinoma proliferation in vitro and in vivo and enhanced the anti-cancer effect of cisplatin.
    PloS one, 2017, Volume: 12, Issue:4

    Topics: Adaptor Proteins, Signal Transducing; Animals; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prol

2017
Metformin-induced alterations in nucleotide metabolism cause 5-fluorouracil resistance but gemcitabine susceptibility in oesophageal squamous cell carcinoma.
    Journal of cellular biochemistry, 2018, Volume: 119, Issue:1

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cell Line, Tumor;

2018
Disulfiram with or without metformin inhibits oesophageal squamous cell carcinoma in vivo.
    Cancer letters, 2018, 03-28, Volume: 417

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Carcinoma, Squamous Cell; Cell L

2018
Antitumor effects of metformin are a result of inhibiting nuclear factor kappa B nuclear translocation in esophageal squamous cell carcinoma.
    Cancer science, 2018, Volume: 109, Issue:4

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cadherins; Carcinoma, Squamous Cell; Cell Line, Tumor; Ce

2018
Metformin suppresses the esophageal carcinogenesis in rats treated with NMBzA through inhibiting AMPK/mTOR signaling pathway.
    Carcinogenesis, 2019, 07-04, Volume: 40, Issue:5

    Topics: AMP-Activated Protein Kinases; Animals; Carcinogenesis; Carcinogens; Cell Proliferation; Dimethylnit

2019
Metformin Inhibited Growth, Invasion and Metastasis of Esophageal Squamous Cell Carcinoma in Vitro and in Vivo.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2018, Volume: 51, Issue:3

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Movement; Cell Proliferation; Down-Regulation

2018
Metformin induces human esophageal carcinoma cell pyroptosis by targeting the miR-497/PELP1 axis.
    Cancer letters, 2019, 05-28, Volume: 450

    Topics: Cell Proliferation; Co-Repressor Proteins; Disease Progression; Down-Regulation; Esophageal Neoplasm

2019
Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma.
    Nature communications, 2019, 03-21, Volume: 10, Issue:1

    Topics: Animals; Antineoplastic Agents; Benzeneacetamides; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent Kin

2019
High metabolic rate and stem cell characteristics of esophageal cancer stem-like cells depend on the Hsp27-AKT-HK2 pathway.
    International journal of cancer, 2019, 10-15, Volume: 145, Issue:8

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Deoxyglucose; Esophageal Neoplasms; Gene Expression Regu

2019
Case-control analysis on metformin and cancer of the esophagus.
    Cancer causes & control : CCC, 2013, Volume: 24, Issue:10

    Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Esophageal Neoplasms; Humans; Hypoglycemic Age

2013
Metformin inhibits esophagus cancer proliferation through upregulation of USP7.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2013, Volume: 32, Issue:5

    Topics: AMP-Activated Protein Kinases; Antineoplastic Agents; Cell Line, Tumor; Cyclin D1; Cyclin-Dependent

2013
Metformin promotes autophagy and apoptosis in esophageal squamous cell carcinoma by downregulating Stat3 signaling.
    Cell death & disease, 2014, Feb-27, Volume: 5

    Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Apoptosis; Autophagy; Carcinoma, Squa

2014
Metformin sensitizes chemotherapy by targeting cancer stem cells and the mTOR pathway in esophageal cancer.
    International journal of oncology, 2014, Volume: 45, Issue:2

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Blot

2014
Metformin induces an intracellular reductive state that protects oesophageal squamous cell carcinoma cells against cisplatin but not copper-bis(thiosemicarbazones).
    BMC cancer, 2014, May-05, Volume: 14

    Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Cell Cycle Checkpoints; Cell Line, Tumor; Cell Prol

2014
Screening of alternative drugs to the tumor suppressor miR-375 in esophageal squamous cell carcinoma using the connectivity map.
    Oncology, 2014, Volume: 87, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Benzocaine; Betazole; Carcinoma, Squamous Cell; Catechin; Cell Lin

2014
Metformin use and the risk of esophageal cancer in Barrett esophagus.
    Southern medical journal, 2014, Volume: 107, Issue:12

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Barrett Esophagus; Case-Control Studies; Diabetes Me

2014
Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo.
    International journal of oncology, 2015, Volume: 46, Issue:5

    Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Blotting, Western; Cell Line, Tumor; Cell Proliferat

2015
Impact of comorbidities and use of common medications on cancer and non-cancer specific survival in esophageal carcinoma.
    BMC cancer, 2015, Volume: 15

    Topics: Adult; Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Ster

2015
Disulfiram/copper-disulfiram Damages Multiple Protein Degradation and Turnover Pathways and Cytotoxicity is Enhanced by Metformin in Oesophageal Squamous Cell Carcinoma Cell Lines.
    Journal of cellular biochemistry, 2015, Volume: 116, Issue:10

    Topics: Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Proliferation; Copper; Disulfiram; Drug Synergism;

2015
Can metformin improve 'the tomorrow' of patients treated for oesophageal cancer?
    European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology, 2015, Volume: 41, Issue:10

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2015
Metformin Induced AMPK Activation, G0/G1 Phase Cell Cycle Arrest and the Inhibition of Growth of Esophageal Squamous Cell Carcinomas In Vitro and In Vivo.
    PloS one, 2015, Volume: 10, Issue:7

    Topics: AMP-Activated Protein Kinases; Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Line, Tumo

2015
Metformin Use During Treatment of Potentially Curable Esophageal Cancer Patients is not Associated with Better Outcomes.
    Annals of surgical oncology, 2015, Volume: 22 Suppl 3

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carb

2015
Rates and predictors of progression to esophageal carcinoma in a large population-based Barrett's esophagus cohort.
    Gastrointestinal endoscopy, 2016, Volume: 84, Issue:1

    Topics: Adenocarcinoma; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Barrett Esophagus; Body

2016
Metformin Synergistically Enhances Cisplatin-Induced Cytotoxicity in Esophageal Squamous Cancer Cells under Glucose-Deprivation Conditions.
    BioMed research international, 2016, Volume: 2016

    Topics: AMP-Activated Protein Kinases; Apoptosis; Carcinoma, Squamous Cell; Cell Line, Tumor; Cell Prolifera

2016
Metformin inhibits the radiation-induced invasive phenotype of esophageal squamous cell carcinoma.
    International journal of oncology, 2016, Volume: 49, Issue:5

    Topics: Apoptosis; Blotting, Western; Carcinoma, Squamous Cell; Cell Adhesion; Cell Movement; Cell Prolifera

2016
Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells
    Cancer research and treatment, 2017, Volume: 49, Issue:3

    Topics: Animals; Antineoplastic Agents; Apoptosis; Carrier Proteins; Cell Cycle Checkpoints; Cell Line, Tumo

2017
Metformin and esophageal cancer risk in Taiwanese patients with type 2 diabetes mellitus.
    Oncotarget, 2017, Mar-21, Volume: 8, Issue:12

    Topics: Adult; Aged; Diabetes Mellitus, Type 2; Esophageal Neoplasms; Female; Humans; Hypoglycemic Agents; I

2017
Metformin use and improved response to therapy in esophageal adenocarcinoma.
    Acta oncologica (Stockholm, Sweden), 2013, Volume: 52, Issue:5

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Chemoradiotherapy; Diabetes Complications; Diabetes

2013
Antitumor effect of metformin in esophageal cancer: in vitro study.
    International journal of oncology, 2013, Volume: 42, Issue:2

    Topics: Antineoplastic Agents; Cell Cycle Proteins; Cell Line, Tumor; Cell Proliferation; Esophageal Neoplas

2013